1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Xia Zhongjun: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
Multiple Myeloma (1)
Bortezomib (1) · Dexamethasone (1) · Lenalidomide (1) · dexamethasone acetate (1) · selinexor (1)
China (1)